Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets

Approximately 75% of breast cancers are estrogen receptor alpha (ERα)-positive and are treatable with endocrine therapies, but often patients develop lethal resistant disease. Frequent mutations (10–40%) in the ligand-binding domain (LBD) codons in the gene encoding ERα (ESR1) have been identified,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gates, Leah A., Gu, Guowei, Chen, Yue, Rohira, Aarti D., Lei, Jonathan T., Hamilton, Ross A., Yu, Yang, Lonard, David M., Wang, Jin, Wang, Shu-Ping, Edwards, David G., Lavere, Philip F., Shao, Jiangyong, Yi, Ping, Jain, Antrix, Jung, Sung Yun, Malovannaya, Anna, Li, Shunqiang, Shao, Jieya, Roeder, Robert G., Ellis, Matthew J., Qin, Jun, Fuqua, Suzanne A. W., O’Malley, Bert W., Foulds, Charles E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095836/
https://www.ncbi.nlm.nih.gov/pubmed/29748621
http://dx.doi.org/10.1038/s41388-018-0284-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095836/
https://www.ncbi.nlm.nih.gov/pubmed/29748621
http://dx.doi.org/10.1038/s41388-018-0284-2

Ejemplares similares